Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA
Vangelis Karalis(National and Kapodistrian University of Athens), Panos Macheras(National and Kapodistrian University of Athens), Mira Symillides(National and Kapodistrian University of Athens)
Cited by 68
Related Papers
The Integration of Artificial Intelligence into Clinical Practice
|Applied Biosciences|2024|225
Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease
|The American Journal of Medicine|2021|122
3D-Printed Oral Dosage Forms: Mechanical Properties, Computational Approaches and Applications
|Pharmaceutics|2021|78
Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability
|Pharmaceutical Research|2008|64
Variational Autoencoders for Data Augmentation in Clinical Studies
|Applied Sciences|2023|54